Lyell Immunopharma, Inc. (LYEL)
- Previous Close
2.7700 - Open
2.8200 - Bid 2.7400 x 200
- Ask 2.7900 x 100
- Day's Range
2.7050 - 2.8200 - 52 Week Range
1.3200 - 3.9700 - Volume
295,362 - Avg. Volume
844,003 - Market Cap (intraday)
701.082M - Beta (5Y Monthly) -0.55
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.33
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
lyell.comRecent News: LYEL
Performance Overview: LYEL
Trailing total returns as of 5/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LYEL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LYEL
Valuation Measures
Market Cap
702.36M
Enterprise Value
231.22M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.27k
Price/Book (mrq)
1.17
Enterprise Value/Revenue
3.46k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-18.93%
Return on Equity (ttm)
-32.93%
Revenue (ttm)
68k
Net Income Avi to Common (ttm)
-228.34M
Diluted EPS (ttm)
-0.9000
Balance Sheet and Cash Flow
Total Cash (mrq)
526.3M
Total Debt/Equity (mrq)
10.25%
Levered Free Cash Flow (ttm)
-84.2M